Survodutide
GLP-1 / metabolic · By Preptide Pro editorial team · Last updated
Survodutide is a glp-1 / metabolic peptide, and it is not FDA-approved. An investigational dual glucagon and GLP-1 receptor agonist. In clinical trials for obesity and liver disease (MASH).
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 171378821 |
|---|---|
| CAS number | 2805997-46-8 |
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4232 g/mol |
| Other names | Survodutide, BI-456906, GLXC-27923 |
Is Survodutide FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Survodutide?
PubMed lists 93 records for “survodutide”, of which 10 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Renal Effects of Dual GLP-1/Glucagon Receptor Agonism: How Should We SYNCHRONIZE With Emerging Evidence in Type 2 Diabetes and Obesity? | Diabetes Obes Metab | 2026 Nov 2 |
| Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties. | Contemp Clin Trials | 2026 Nov |
| Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides. | AAPS J | 2026 Oct 30 |
| Interpreting Survodutide Renoprotection in a Hyperfiltration Model. | Diabetes Obes Metab | 2026 Oct 19 |
| Antidiabetic medications in the pipeline. | Hormones (Athens) | 2026 Oct 19 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.